KalVista Pharmaceuticals Inc’s recent filing unveils that its CHIEF EXECUTIVE OFFICER Palleiko Benjamin L unloaded Company’s shares for reported $79828.0 on Mar 07 ’25. In the deal valued at $11.97 per share,6,669 shares were sold. As a result of this transaction, Palleiko Benjamin L now holds 287,811 shares worth roughly $3.21 million.
Then, Audhya Paul K. sold 2,394 shares, generating $23,988 in total proceeds. Upon selling the shares at $10.02, the CHIEF MEDICAL OFFICER now owns 102,940 shares.
Before that, Yea Christopher sold 1,918 shares. KalVista Pharmaceuticals Inc shares valued at $19,218 were divested by the CHIEF DEVELOPMENT OFFICER at a price of $10.02 per share. As a result of the transaction, Yea Christopher now holds 93,952 shares, worth roughly $1.05 million.
JMP Securities initiated its KalVista Pharmaceuticals Inc [KALV] rating to a Mkt outperform in a research note published on January 31, 2025; the price target was $19. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. BofA Securities began covering KALV with “Buy” recommendation on December 18, 2024. H.C. Wainwright started covering the stock on June 15, 2020. It rated KALV as “a Buy”.
Price Performance Review of KALV
On Tuesday, KalVista Pharmaceuticals Inc [NASDAQ:KALV] saw its stock fall -3.34% to $11.15. Over the last five days, the stock has lost -10.76%. KalVista Pharmaceuticals Inc shares have risen nearly 31.70% since the year began. Nevertheless, the stocks have fallen -5.94% over the past one year. While a 52-week high of $15.50 was reached on 03/12/25, a 52-week low of $7.30 was recorded on 01/13/25. SMA at 50 days reached $10.66, while 200 days put it at $11.10.
Levels Of Support And Resistance For KALV Stock
The 24-hour chart illustrates a support level at 10.86, which if violated will result in even more drops to 10.56. On the upside, there is a resistance level at 11.62. A further resistance level may holdings at 12.08. The Relative Strength Index (RSI) on the 14-day chart is 44.30, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.56, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.15%. Stochastics %K at 18.91% indicates the stock is a buying.
How much short interest is there in KalVista Pharmaceuticals Inc?
A steep rise in short interest was recorded in KalVista Pharmaceuticals Inc stocks on 2025-03-14, growing by 5561.0 shares to a total of 5.84 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 5.83 million shares. There was a rise of 0.1%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 29, 2019 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $31 price target.
